Vertex Pharmaceuticals (NASDAQ:VRTX) EVP Sells $886,327.75 in Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Jonathan Biller sold 1,925 shares of the business’s stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $460.43, for a total value of $886,327.75. Following the transaction, the executive vice president owned 20,819 shares in the company, valued at $9,585,692.17. The trade was a 8.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $491.47 on Friday. The stock’s 50 day moving average price is $459.98 and its 200 day moving average price is $427.48. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The company has a market cap of $124.70 billion, a PE ratio of 32.06 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.05 by ($0.02). The business had revenue of $3.19 billion during the quarter, compared to analysts’ expectations of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.90% and a net margin of 32.94%.The company’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.98 EPS. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Analyst Ratings Changes

VRTX has been the topic of several research analyst reports. Sanford C. Bernstein reissued an “outperform” rating and set a $577.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday. Royal Bank Of Canada reduced their price objective on Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating for the company in a report on Friday. Leerink Partners upped their target price on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an “outperform” rating in a report on Monday, December 29th. Evercore raised their price target on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the company an “outperform” rating in a research report on Friday, January 23rd. Finally, Scotiabank boosted their price objective on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the stock an “outperform” rating in a research report on Friday. Twenty-two equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $537.05.

Institutional Trading of Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VRTX. Police & Firemen s Retirement System of New Jersey boosted its position in shares of Vertex Pharmaceuticals by 3.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 39,035 shares of the pharmaceutical company’s stock worth $17,378,000 after buying an additional 1,393 shares during the period. Bailard Inc. lifted its stake in Vertex Pharmaceuticals by 0.5% in the 2nd quarter. Bailard Inc. now owns 38,147 shares of the pharmaceutical company’s stock worth $16,983,000 after acquiring an additional 200 shares in the last quarter. Leuthold Group LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter worth about $5,030,000. Advisory Resource Group purchased a new position in Vertex Pharmaceuticals during the 3rd quarter valued at about $1,286,000. Finally, Generali Asset Management SPA SGR increased its holdings in shares of Vertex Pharmaceuticals by 41.8% in the 3rd quarter. Generali Asset Management SPA SGR now owns 23,569 shares of the pharmaceutical company’s stock valued at $9,231,000 after purchasing an additional 6,942 shares during the period. Hedge funds and other institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.